title: Candidemia in the pediatric patient with burns.
abstract: The incidence of candidemia in patients with burns appears to be falling. However, when it occurs it remains a significant cause of morbidity and a potential cause of death. A 5-year retrospective review revealed that 138 (14.4%) of 962 pediatric patients who had been acutely burned had Candida species isolated from one or more sites during their hospital stay, but candidemia developed in only 17 patients (12.3% of those from whom Candida species were recovered and 1.8% of all admissions). Patients from whom Candida species were recovered at one site had a 0% incidence of candidemia, those from whom Candida species were recovered at two sites had a 22.2% incidence of candidemia, and those from whom Candida species were recovered at three or more sites had a 34.4% incidence of candidemia. These differences were significant by chi-square analysis (p < 0.0001). There was a low mortality rate associated with candidemia, with only one (5.9%) of the 17 patients dying as a direct result of invasive Candida infection. Nystatin administered enterally did not prevent the development of candidemia. Our review suggests that delay in biologic wound closure and exposure to broad-spectrum antibiotics are associated with an enhanced risk of candidemia. Wound closure and systemically administered amphotericin B remain the mainstays of therapy.
authors.affiliation: Shriners Burns Institute, Boston, MA 02114, USA.
authors.forename: R L
authors.initials: RL
authors.lastname: Sheridan
authors.forename: J M
authors.initials: JM
authors.lastname: Weber
authors.forename: L G
authors.initials: LG
authors.lastname: Budkevich
authors.forename: R G
authors.initials: RG
authors.lastname: Tompkins
mesh_terms: D000293:Adolescent; D000935:Antifungal Agents / Q000008:administration & dosage / Q000627:therapeutic use; D002056:Burns / Q000150:complications* / Q000382:microbiology / Q000401:mortality; D002177:Candidiasis / Q000150:complications* / Q000188:drug therapy / Q000401:mortality / Q000517:prevention & control; D002648:Child; D002675:Child, Preschool; D005260:Female; D016469:Fungemia / Q000150:complications* / Q000188:drug therapy / Q000401:mortality / Q000517:prevention & control; D006801:Humans; D007223:Infant; D008297:Male; D009761:Nystatin / Q000008:administration & dosage / Q000627:therapeutic use; D012307:Risk Factors; D015996:Survival Rate
chemical_list: D000935:Antifungal Agents; D009761:Nystatin